Palbociclib Approved for HR-positive, HER2-positive Advanced Breast Cancer
Palbociclib is the first CDK4/6 inhibitor approved for HR-positive, HER2-positive advanced breast cancer. The U.S. Food and Drug Administration...
Progress Against Cancer
Palbociclib is the first CDK4/6 inhibitor approved for HR-positive, HER2-positive advanced breast cancer. The U.S. Food and Drug Administration...
Afamitresgene autoleucel was granted full approval with an expanded indication for certain adult and pediatric patients with advanced synovial...
Under new approval, the drug can be given with immunotherapy to help reduce risk of recurrence after surgery in...
The FDA approved pivekimab sunirine-pvzy for the treatment of the rare blood cancer BPDCN. The U.S. Food and Drug...
Datopotamab deruxtecan-dlnk was approved to treat PD-1/PD-L1 inhibitor-ineligible, advanced triple-negative breast cancer. The U.S. Food and Drug Administration (FDA)...
The FDA has approved fam-trastuzumab deruxtecan-nxki for neoadjuvant or adjuvant treatment of HER2-positive early-stage breast cancer. The U.S. Food...
The FDA has approved atezolizumab or atezolizumab and hyaluronidase-tqjs as adjuvant therapy for muscle-invasive bladder cancer. The U.S. Food...
The BCL-2 inhibitor received accelerated approval for patients with relapsed or refractory mantle cell lymphoma. The U.S. Food and...
The bispecific antibody was approved for certain patients whose bile duct cancer harbors gene fusions that involve the neuregulin...
Vepdegestrant is the first PROTAC approved for any cancer indication. The U.S. Food and Drug Administration (FDA) approved vepdegestrant...